ReviewBiomarker research2023
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges.
Review in Biomarker research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 53 citations in OpenAlex.
- Technical review of artificial intelligence in TCR-T therapy.Journal of the National Cancer Center · 2026Review
- Multiomics prediction and immunogenic validation of personalized neoantigens in cholangiocarcinoma patients.Journal of translational medicine · 2026Article
- A bibliometric analysis of global research trends in adoptive cell therapy for triple negative breast cancer over the past 15 years.Discover oncology · 2026Article
- Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications.Cancer medicine · 2026Review
- Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines.Cancer cell international · 2026Review
- Progress in cell-based immunotherapies for solid tumors.Discover oncology · 2026Review
- Molecular origin, discovery, validation and application of neoantigens.Asian journal of pharmaceutical sciences · 2026Review
- Decoding TCR recognition via geometric deep learning of immunological fingerprints.Briefings in bioinformatics · 2026Article
- KRASScience advances · 2026Article
- Cell therapy in sarcoma: current landscape and future directions.Journal for immunotherapy of cancer · 2026Review
- Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026Review
- T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials.Frontiers in immunology · 2026Review
- FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.Cancers · 2025Review
- An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer.Oncoimmunology · 2025Article
- Neoantigen mRNA vaccines and AHuman vaccines & immunotherapeutics · 2025Review
- Computational neoantigen prediction for cancer immunotherapy.Genes and immunity · 2025Review
- Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy.Biomarker research · 2025Review
- Immunotherapy research for prostate cancer from 2000 to 2024: a bibliometric and visualization analysis.Translational andrology and urology · 2025Article
- Neoantigen identification and TCR-T therapy development for solid tumors: current advances and future perspectives.Journal of the National Cancer Center · 2025Article
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Adoptive cell therapy using T cell receptor-engineered T cells (TCR-T) is a promising approach for cancer therapy with an expectation of no significant side effects. In the human body, mature T cells are armed with an incredible diversity of T cell receptors (TCRs) that theoretically react to the variety of random mutations generated by tumor cells. The outcomes, however, of current clinical trials using TCR-T cell therapies are not very successful especially involving solid tumors. The therapy still faces numerous challenges in the efficient screening of tumor-specific antigens and their cognate TCRs. In this review, we first introduce TCR structure-based antigen recognition and signaling, then describe recent advances in neoantigens and their specific TCR screening technologies, and finally summarize ongoing clinical trials of TCR-T therapies against neoantigens. More importantly, we also present the current challenges of TCR-T cell-based immunotherapies, e.g., the safety of viral vectors, the mismatch of T cell receptor, the impediment of suppressive tumor microenvironment. Finally, we highlight new insights and directions for personalized TCR-T therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.